C.M. Woodroffe

920 total citations
14 papers, 711 citations indexed

About

C.M. Woodroffe is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Surgery. According to data from OpenAlex, C.M. Woodroffe has authored 14 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in C.M. Woodroffe's work include Lung Cancer Treatments and Mutations (5 papers), Testicular diseases and treatments (4 papers) and Lung Cancer Research Studies (4 papers). C.M. Woodroffe is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Testicular diseases and treatments (4 papers) and Lung Cancer Research Studies (4 papers). C.M. Woodroffe collaborates with scholars based in United Kingdom. C.M. Woodroffe's co-authors include M.H. Cullen, A.D. Chetiyawardana, Lucinda Billingham, M.H. Cullen, E.M. Bessell, D. Ferry, C.K. Connolly, Richard G. Grundy, N.H. Gower and J. E. Cook and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C.M. Woodroffe

14 papers receiving 677 citations

Peers

C.M. Woodroffe
V.J. Harvey New Zealand
Ignazio Carreca Italy
Vittorio Franciosi Italy
S Sörenson Sweden
C Skosey United States
W. J. Stuckey United States
Uzair B. Chaudhary United States
Franco Testore Italy
C. P. J. Vendrik Netherlands
Regina Gironés Spain
V.J. Harvey New Zealand
C.M. Woodroffe
Citations per year, relative to C.M. Woodroffe C.M. Woodroffe (= 1×) peers V.J. Harvey

Countries citing papers authored by C.M. Woodroffe

Since Specialization
Citations

This map shows the geographic impact of C.M. Woodroffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.M. Woodroffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.M. Woodroffe more than expected).

Fields of papers citing papers by C.M. Woodroffe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.M. Woodroffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.M. Woodroffe. The network helps show where C.M. Woodroffe may publish in the future.

Co-authorship network of co-authors of C.M. Woodroffe

This figure shows the co-authorship network connecting the top 25 collaborators of C.M. Woodroffe. A scholar is included among the top collaborators of C.M. Woodroffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.M. Woodroffe. C.M. Woodroffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Cullen, M.H., Lucinda Billingham, C.M. Woodroffe, et al.. (1999). Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life. Journal of Clinical Oncology. 17(10). 3188–3194. 352 indexed citations
2.
3.
Cullen, M.H., Lucinda Billingham, C.M. Woodroffe, et al.. (1997). 10 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 1. Results of a randomised trial in patients with localised, inoperable disease. Lung Cancer. 18. 5–5. 3 indexed citations
4.
Billingham, Lucinda, M.H. Cullen, Jack Woods, et al.. (1997). 26 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluating palliation & quality of life. Lung Cancer. 18. 9–10. 17 indexed citations
5.
Cullen, M.H., C.M. Woodroffe, Lucinda Billingham, et al.. (1997). 11 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 2. Results of a randomised trial in patients with extensive disease. Lung Cancer. 18. 5–5. 9 indexed citations
6.
Cullen, M.H., N Stuart, C.M. Woodroffe, et al.. (1994). ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.. Journal of Clinical Oncology. 12(4). 779–787. 20 indexed citations
7.
Woodroffe, C.M., Simon R. M. Jones, & M.H. Cullen. (1991). A case of spontaneous regression of metastatic testicular teratoma. Clinical Oncology. 3(1). 46–48. 2 indexed citations
8.
Woodroffe, C.M., et al.. (1990). Long-term toxicity of chemotherapy for testicular cancer – the cost of cure. British Journal of Cancer. 61(3). 479–484. 71 indexed citations
9.
Stuart, N, Richard G. Grundy, C.M. Woodroffe, & M.H. Cullen. (1990). Quality of life after treatment for testicular cancer—the patient's view. European Journal of Cancer and Clinical Oncology. 26(3). 291–294. 25 indexed citations
10.
Cullen, M.H., et al.. (1989). The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. British Journal of Cancer. 60(5). 759–763. 11 indexed citations
11.
Cullen, M.H., et al.. (1988). Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. British Journal of Cancer. 58(3). 359–361. 101 indexed citations
12.
Cullen, M.H., et al.. (1988). Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime. British Journal of Urology. 62(5). 454–460. 18 indexed citations
13.
Cullen, M.H., et al.. (1987). Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease.. PubMed. 71(12). 1227–30. 25 indexed citations
14.
Cullen, Michael, D.A.L. Morgan, Walter M. Gregory, et al.. (1986). Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial. Cancer Chemotherapy and Pharmacology. 17(2). 157–160. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V.J. Harvey Breakdown of academic impact, for papers by Ignazio Carreca Breakdown of academic impact, for papers by Vittorio Franciosi Breakdown of academic impact, for papers by S Sörenson Breakdown of academic impact, for papers by C Skosey Breakdown of academic impact, for papers by W. J. Stuckey Breakdown of academic impact, for papers by Uzair B. Chaudhary Breakdown of academic impact, for papers by Franco Testore Breakdown of academic impact, for papers by C. P. J. Vendrik Breakdown of academic impact, for papers by Regina Gironés
Rankless by CCL
2026